Partial clinical response to anakinra in severe palmoplantar pustular psoriasis
- 7 August 2014
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 171 (3) , 646-649
Abstract
Palmoplantar pustular psoriasis is a clinical psoriasis variant characterised by a high impact on quality of life and poor response to biologics approved for plaque type psoriasis.The recombinant interleukin-1 (IL-1) receptor antagonist anakinra has been recently used for the treatment of isolated refractory cases of generalised pustular psoriasis with contrasted results. To report the clinical response in two patients treated with anakinra as salvage therapy in two patients with severe palmoplantar pustular psoriasis refractory to currently available antipsoriatic systemic therapies. Anakinra was given subcutaneously at the daily dose of 100 mg, and clinical response was evaluated using the palmoplantar psoriasis area and severity index (PPPASI). Only partial and transient responses were observed in both patients, who had to stop anakinra due to lack of efficacy and to side effects. Anakinra appears to provide only partial clinical improvement in refractory palmoplantar pustular psoriasis. Prospective clinical studies on larger populations are warranted to investigate more accurately both efficacy and safety of IL-1-inhibiting strategies in pustular psoriasis.Keywords
This publication has 16 references indexed in Scilit:
- Successful therapy with anakinra in a patient with generalized pustular psoriasis carryingIL36RNmutationsBritish Journal of Dermatology, 2014
- First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With AnakinraPediatrics, 2013
- Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular PhenotypesJournal of Investigative Dermatology, 2013
- Efficacy of ustekinumab in refractory palmoplantar pustular psoriasisBritish Journal of Dermatology, 2012
- Acitretin- and Tumor Necrosis Factor Inhibitor –Resistant Acrodermatitis Continua of Hallopeau Responsive to the Interleukin 1 Receptor Antagonist AnakinraArchives of Dermatology, 2012
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular PsoriasisNew England Journal of Medicine, 2011
- Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN MutationsAnnals of Internal Medicine, 2010
- An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor AntagonistNew England Journal of Medicine, 2009
- Successful Treatment of Recalcitrant Palmoplantar Pustular Psoriasis with Sequential Use of Infliximab and AdalimumabDermatology, 2009
- Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled studyBritish Journal of Dermatology, 2001